Head-To-Head Contrast: Evaxion Biotech A/S (NASDAQ:EVAX) & ProKidney (NASDAQ:PROK)

Evaxion Biotech A/S (NASDAQ:EVAX) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Analyst Recommendations

This is a summary of recent ratings and price targets for Evaxion Biotech A/S and ProKidney, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
ProKidney	0	3	2	0	2.40

Evaxion Biotech A/S currently has a consensus price target of $11.00, indicating a potential upside of 278.01%. ProKidney has a consensus price target of $4.50, indicating a potential upside of 167.86%. Given Evaxion Biotech A/S’s stronger consensus rating and higher probable upside, research analysts clearly believe Evaxion Biotech A/S is more favorable than ProKidney.

Insider & Institutional Ownership

11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Comparatively, 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Evaxion Biotech A/S has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Profitability

This table compares Evaxion Biotech A/S and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	N/A	-108.14%
ProKidney	N/A	N/A	-8.80%

Earnings & Valuation

This table compares Evaxion Biotech A/S and ProKidney”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	$278,000.00	58.39	-$22.12 million	($2.35)	-1.24
ProKidney	N/A	N/A	-$35.47 million	($0.57)	-2.95

Evaxion Biotech A/S has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Evaxion Biotech A/S beats ProKidney on 6 of the 10 factors compared between the two stocks.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.